SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%

Wedbush Downgrades Unum Therapeutics to Neutral, Lowers Price Target to $1

Wedbush analyst David Nierengarten downgrades Unum Therapeutics (NASDAQ:UMRX) from Outperform to Neutral and lowers the price target from $7 to $1.

Benzinga · 03/04/2020 11:28

Wedbush analyst David Nierengarten downgrades Unum Therapeutics (NASDAQ:UMRX) from Outperform to Neutral and lowers the price target from $7 to $1.